ImmunoGen, Inc. (IMGN) Reports Second Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update  
1/25/2013 6:22:25 AM

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today reported financial results for the three-month period ended December 31, 2012 – the second quarter of the Company’s 2013 fiscal year – and provided an update on the Company.